- Home
- FORTY vs CELC Comparison
FORTY vs CELC Comparison
Compare FORTY & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORTY
- CELC
- Stock Information
- Founded
- FORTY 1985
- CELC 2011
- Country
- FORTY Israel
- CELC United States
- Employees
- FORTY N/A
- CELC N/A
- Industry
- FORTY EDP Services
- CELC Medical Specialities
- Sector
- FORTY Technology
- CELC Health Care
- Exchange
- FORTY Nasdaq
- CELC Nasdaq
- Market Cap
- FORTY 2.1B
- CELC 2.3B
- IPO Year
- FORTY 1997
- CELC 2017
- Fundamental
- Price
- FORTY $139.45
- CELC $54.60
- Analyst Decision
- FORTY
- CELC Strong Buy
- Analyst Count
- FORTY 0
- CELC 5
- Target Price
- FORTY N/A
- CELC $53.60
- AVG Volume (30 Days)
- FORTY 439.0
- CELC 888.2K
- Earning Date
- FORTY 08-19-2025
- CELC 11-13-2025
- Dividend Yield
- FORTY 1.02%
- CELC N/A
- EPS Growth
- FORTY 15.06
- CELC N/A
- EPS
- FORTY 4.97
- CELC N/A
- Revenue
- FORTY $2,889,481,000.00
- CELC N/A
- Revenue This Year
- FORTY N/A
- CELC N/A
- Revenue Next Year
- FORTY N/A
- CELC N/A
- P/E Ratio
- FORTY $26.23
- CELC N/A
- Revenue Growth
- FORTY 8.58
- CELC N/A
- 52 Week Low
- FORTY $70.52
- CELC $7.58
- 52 Week High
- FORTY $149.09
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- FORTY 58.31
- CELC 57.48
- Support Level
- FORTY $136.71
- CELC $52.90
- Resistance Level
- FORTY $149.09
- CELC $63.06
- Average True Range (ATR)
- FORTY 1.01
- CELC 3.26
- MACD
- FORTY 0.55
- CELC -1.17
- Stochastic Oscillator
- FORTY 61.58
- CELC 32.96
About FORTY Formula Systems (1985) Ltd.
Formula Systems (1985) Ltd is a holding company that, through its subsidiaries, provides information technology services. The company organizes itself into operating segments: The Matrix segment, which generates the majority of revenue, provides software development and existing software expansion services. The Sapiens segment provides software development services for the insurance industry. The Magic Software segment provides vendor management systems and workforce management services, which include accounting and finance, human resources, Michpal, ZAP Group, and Others. The majority of the company's revenue comes from Israel.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.